Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (GB:0JXI)
LSE:0JXI
RESEARCH TOOLSreports
Madrigal Pharmaceuticals (0JXI) Share Price & Analysis
0 Followers
0JXI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$122.87 - $316.00
Previous Close$214.67
Volume143.00
Average Volume (3M)390.00
Market Cap
$4.48B
Enterprise Value$4.37B
Total Cash (Recent Filing)$232.35M
Total Debt (Recent Filing)$116.56M
Price to Earnings (P/E)-10.8
Beta2.95
Next Earnings
May 07, 2024EPS Estimate
-$6.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.93
Shares Outstanding19,897,425
10 Day Avg. Volume23
30 Day Avg. Volume390
Standard Deviation0.24
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)10.41
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.14
Forecast
1Y Price Target
$375.07Price Target Upside74.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Madrigal Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialRezdiffra is now available in the US as the first and only approved therapy to treat nonalcoholic steatohepatitis (NASH), indicating a unique position in a growing market.
Insurance Coverage And AccessUnited Healthcare's inclusion of Rezdiffra in its Pharmacy Benefit Programs Drug List should facilitate patient access to the drug, potentially accelerating adoption.
Sales And Revenue ProjectionsAnalyst predicts 2024 revenue of $97M for MDGL, surpassing the consensus of $89M, reflecting strong demand for Rezdiffra based on recent physician surveys.
Bears Say
Market Reaction And CompetitionMDGL shares have decreased significantly, which reflects the market's reaction to competing NASH data.
Pricing And Access ChallengesThe $47k per patient per year price tag for Rezdiffra is at the higher end of cost-effectiveness analyses, which could result in commercial barriers.
Regulatory And Clinical UncertaintiesContinued approval of Rezdiffra is contingent upon verification and description of clinical benefit in confirmatory trials.
---
0JXI FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest share price was $122.87 and its highest was $316.00 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2024 which is in 13 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Feb 28, 2024. The company reported -$5.68 earnings per share for the quarter, missing the consensus estimate of -$5.239 by -$0.441.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -$6.22.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 20,993,578 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$5.68 in its last earnings report, missing expectations of -$5.239. Following the earnings report the stock price went up 3.839%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Madrigal Pharmaceuticals Inc’s shares valued at 456M.
---
Madrigal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$375.07 (74.72% Upside)
$375.07 (74.72% Upside)
Blogger Sentiment
Bullish
GB:0JXI Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.65%
12-Months-Change
Fundamentals
Return on Equity
-123.98%
Trailing 12-Months
Asset Growth
76.67%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
0JXI Stock 12 Months Forecast
Average Price Target
$375.07
▲(74.72% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Amarin
―
Arrowhead Pharmaceuticals
―
Corbus Pharmaceuticals
―
Galmed Pharmaceuticals
―
Best Analysts Covering 0JXI
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+13.99%
assigned a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +13.99% per trade.
---